Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2008

Wu Jenn-Yu, Wu Shang-Gin, Yang Chih-Hsin, Gow Chien-Hung, Chang Yih-Leong, Yu Chong-Jen, Shih Jin-Yuan, Yang Pan-Chyr

Abstract excerpt

PURPOSE: Clinical reports about responsiveness to gefitinib treatment in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited. To increase understanding of the influence of exon 20 mutations on NSCLC treatment with gefitinib, we investigated the clinical features of lung cancer in patients with exon 20 mutations and analyzed the gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Quinazolines

Share to Treatment Outcome

Source

Identifiers

PMID: 18676761
DOI: 10.1158/1078-0432.CCR-07-5123

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.PMID 18676761Read ↗

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatmentSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.Semantic proximity Read ↗

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring <em>EGFR</em> exon 20 mutationsSemantic proximity Read ↗

EGFR exon 20 insertion mutation in Japanese lung cancer.Semantic proximity Read ↗

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.Semantic proximity Read ↗

[First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion].Semantic proximity Read ↗

[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.Semantic proximity Read ↗

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in KoreaSemantic proximity Read ↗

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.Semantic proximity Read ↗

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.